DOCSLIB.ORG

Compound Name

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Georgia State Crime Lab Drug Library Index Number Compound Name Index Number Compound Name 1 Cocaine .HCl 29 2,5- 2 Phencyclidine .HCl Dimethoxyamphetamine 3 1-(1- .HCl Phenylcyclohexyl)morpholi 30 Dextromethorphan ne .HCl 31 Nitrazepam 4 Amphetamine .HCl 32 Clonazepam 5 Lysergic acid diethylamide; 33 Diethyltryptamine .HCl LSD 34 Cannabinol 6 Heroin; Diacetylmorphine 35 Cannabigerol 7 1-(1- 36 Ethchlorvynol Phenylcyclohexyl)pyrrolidin 37 Cannabidiol e .HCl 38 Cannabicyclol 8 1-(1-(2- 39 Methaqualone Thienyl)cyclohexyl)pyrrolidi 40 Lysergic acid ne .HCl 41 4-Methoxyamphetamine 9 1-(1-(2- .HCl Thienyl)cyclohexyl)morphol 42 2-Methoxy-4,5- ine .HCl methylenedioxyamphetami 10 1-(1-(2- ne .HCl Thienyl)cyclohexyl)piperidi 43 Thioridazine .HCl ne; TCP 44 3,4,5- 11 Psilocybin Trimethoxyamphetamine 12 Psilocin 45 2,5-Dimethoxy-4- 13 d-2-Bromolysergic acid ethylamphetamine diethylamide 46 3,4- 14 6-Monoacetylmorphine Methylenedioxyamphetami 15 Heroin .HCl; ne .HCl Diacetylmorphine .HCl 47 Dipropyltryptamine .HCl 16 N-Norcodeine 48 d-Pseudoephedrine .HCl 17 Etonitazene 49 2,5-Dimethoxy-4- 18 Diphenoxylate .HCl methylamphetamine 19 Lysergic acid diethylamide 50 D9-Tetrahydrocannabinol tartrate; LSD tartrate 51 Hydroquinone 20 Formaldehyde 52 D8-Tetrahydrocannabinol 21 l-a-Methadol .HCl; 53 Cannabichromene Dimepheptanol .HCl 54 Methylphenidate .HCl 22 l-a-N-Normethadol .HClO4 55 Diazepam 23 N-Normorphine .HCl 56 Doxepin .HCl 24 Codeine 57 Tetracycline .HCl 25 Dihydromorphine 58 Flurazepam .2HCl 26 Phentermine .HCl 59 7-(2- 27 2,4,5- Chloroethyl)theophylline Trimethoxyamphetamine 60 Pentazocine .HCl 28 2,4,6- 61 Clorazepate dipotassium Trimethoxyamphetamine 62 Codeine phosphate 63 Methamphetamine .HCl Georgia State Crime Lab Drug Library, page 1 of 21 Index Number Compound Name Index Number Compound Name 64 Ethylmorphine .HCl 109 Sucrose 65 Trihexyphenidyl 110 Chlordiazepoxide 66 Vitamin K3; Menadione 111 Chlordiazepoxide .HCl 67 Quinine sulfate 112 Erythromycin stearate 68 Quinine .HCl .2H2O 113 Opium powder 69 Chloral hydrate 114 Ampicillin .3H2O 70 Procaine .HCl 115 Benzphetamine 71 Imipramine 116 Benzphetamine .HCl 72 Chlorpromazine 117 Triprolidine .HCl 73 Diethylpropion 118 Phenytoin 74 Pethidine .HCl; Meperidine 119 Inositol .HCl 120 Lactose powder, hydrous 75 Anileridine .2HCl 121 Dextrose, anhydrous; D- 76 2,4- Glucose, anhydrous Dimethoxyamphetamine 122 Dextrose .H2O; D-Glucose .HCl .H2O 77 Propoxyphene 123 Brucine sulfate 78 Lorazepam 124 Strychnine sulfate 79 Propoxyphene .HCl 125 Homatropine hydrobromide 80 Ethinazone; Etaqualone 126 Quinine .HCl 81 Fenfluramine .HCl 127 Quinidine sulfate 82 Methadone-HCl 128 Saccharin sodium 83 Diethylpropion .HCl 129 Sodium hydroxide 84 Meprobamate 130 Penicillin G potassium 85 Phenmetrazine 131 Oxazepam 86 Phenmetrazine .HCl 132 Triflupromazine .HCl 87 Glutethimide 133 Methapyrilene .HCl 88 Mannitol 134 Thiamine .HCl 89 Dihydrocodeinone 135 Oxycodone .HCl 90 Dihydrocodeinone .HCl 136 Phenylbutazone 91 Phendimetrazine 137 Sulfamethoxazole 92 Phendimetrazine .HCl 138 Mazindol 93 Chloromethaqualone 139 Thiamine .HCl 94 Mecloqualone 140 Oxycodone 95 N-Ethyl-3- 141 Nitrous oxide piperidylbenzilate .HCl 142 Ethinamate 96 Levorphanol 143 Hydroflumethiazide 97 N-Methyl-3- 144 Methyprylon piperidylbenzilate .HCl 145 Sodium bisulfate 98 Mescaline .HCl 146 N-(2- 99 Levorphanol .HCl Cyanoethyl)amphetamine 100 Ibogaine .HCl 147 N-(2- 101 Hydromorphone .HCl Cyanoethyl)amphetamine 102 4-Bromo-2,5- .HCl dimethoxyamphetamine 148 Diphenhydramine .HCl 103 Penicillin V 149 Morphine .HCl 104 Ascorbic acid; Vitamin C 150 Hydroxyurea 105 Benzocaine; Ethyl 4- 151 Clortermine .HCl aminobenzoate 152 Furosemide 106 N-Ethyl-1- 153 Mesoridazine phenylcyclohexylamine benzenesulphonate .HCl 154 Prednisone 107 Ketamine 155 Chloral betaine 108 3,4,5- 156 Sodium thiosulfate Trimethoxybenzaldehyde 157 Prednisolone Georgia State Crime Lab Drug Library, page 2 of 21 Index Number Compound Name Index Number Compound Name 158 Folic acid 205 Phenyltoloxamine citrate 159 Apomorphine .HCl 206 Chlorothiazide 160 Nicotine .HCl 207 Isosorbide dinitrate 161 Propylhexedrine .HCl 208 Scopolamine .HCl 162 m-Carboxybenzotrifluoride 209 Cocaine .HCl 163 l-a-Acetylmethadol .HCl 210 Moxalactam, diammonium 164 Piperonal salt 165 Flurazepam 211 Ethchlorvynol 166 Flurazepam .2HCl 212 Lidocaine 167 Amitriptyline .HCl 213 Mezlocillin sodium .H2O 168 Iopanoic acid 214 Pentazocine 169 Acetylsalicylic acid; Aspirin 215 Primidone 170 Diphenylhydantoin: 216 Dehydrocholic acid Phenytoin 217 Alphenal; phenallymal; 171 Carbromal Allylphenylbarbituric acid 172 Cinchocaine .HCl; 218 Tetracaine Dibucaine .HCl 219 Niclosamide 173 Carisoprodol 220 Phenazocine 174 Chloroquine diphosphate 221 Atabrine .2HCl; Quinacrine 175 Phenacetin .2HCl 176 Floxuridine 222 Alphaprodine .HCl 177 Nortriptyline .HCl 223 Atropine sulfate 178 Cocaine 224 Probenecid 179 Methocarbamol 225 Lidocaine .HCl 180 Mepivacaine .HCl 226 Nalidixic acid 181 Phenformin .HCl 227 Pyrilamine 182 Phencyclidine; PCP 228 Potassium cyanide 183 Acetaminophen 229 Methaqualone .HCl 184 Caffeine 230 Procainamide .HCl 185 Chlorpheniramine maleate 231 Butyl p-aminobenzoate 186 Chlorpheniramine 232 Propranolol 187 Chloroquine 233 Hydroxyzine 188 Meclizine .HCl 234 Flurandrenolide 189 Phenyltoloxamine 235 Paraldehyde 190 5-Methoxy-N,N- 236 a-Chloroacetophenone; CN dimethyltryptamine 237 o- 191 Chlorzoxazone Chlorobenzalmalononitrile 192 Cephalathin sodium 238 Dipyridamole 193 Phenylephrine .HCl 239 Ethyl m-aminobenzoate, 194 Theophylline; 1,3- methanesulfonic acid salt Dimethylxanthine 240 Methyldopa 195 N-Ethyl-1- 241 Ibuprofen phenylcyclohexylamine 242 Perphenazine 196 Doxepin 243 Sulfisoxazole 197 Promethazine .HCl 244 Hydrocortisone 198 Salicylic acid 245 Nitroglycerin 199 Dexbrompheniramine 246 Amoxapine maleate 247 Cephradine, CHCl3 extract 200 Salicylamide 248 Yohimbine .HCl 201 Gentisic acid 249 Diphenhydramine 202 Scopolamine 250 Diphenoxylate 203 3,4- 251 Doxylamine Dihydroxynorephedrine; 252 Choledyl; Choline Norderfin theophyllinate 204 Dexbrompheniramine 253 Trihexyphenidyl .HCl Georgia State Crime Lab Drug Library, page 3 of 21 Index Number Compound Name Index Number Compound Name 254 Caramiphen 304 Cryptenamine tannate 255 Nicotinamide 305 N-Desmethyldiazepam 256 Imipramine 306 1-Hydroxyflurazepam 257 Isonicotinic acid 307 Thiamylal sodium 258 Isonicotinamide 308 Aminopyrine 259 Succinylcholine chloride 309 Mesoridazine .HCl 260 Promethazine 310 Ketamine .HCl 261 Indomethacin 311 Iodipamide 262 Phencyclidine .HCl; 1-(1- 312 Oxyphencyclimine .HCl Phenylcyclohexyl)piperidin 313 Chlorpromazine .HCl e .HCl; PCP .HCl 314 Imipramine .HCl 263 Ethylestrenol 315 Amobarbital 264 17-Methyltestosterone 316 Phenobarbital 265 Oxandrolone 317 Butalbital 266 Oxymetholone 318 Pentobarbital 267 Stanozolol 319 Butabarbital 268 Stanozolol 320 Barbital; 5,5- 269 Trimethobenzamide .HCl Diethylbarbituric acid 270 Trimethobenzamide 321 Secobarbital 271 Cyclobenzaprine 322 Metharbital 272 Hydralazine 323 Doxycycline hyclate 273 Zomepirac 324 Dihydrocodeine 274 Fluphenazine 325 Tolbutamide 275 Benztropine mesylate 326 Indole-3-acetic acid 276 Benztropine 327 Prazepam 277 Zomepirac sodium .2H2O 328 Vancomycin .HCl 278 Fenoprofen 329 Orphenadrine .HCl 279 Rifampin 330 Pethidine; Meperidine 280 (-)-Menthol 331 Pseudoallococaine .HCl 281 Cimetidine 332 Oxymorphone .HCl 282 Dicyclomine 333 Trimethoprim 283 Mepivacaine 334 Sulindac 284 Mescaline sulfate .2H2O 335 Oxyphenbutazone 285 Phenethylamine .HCl 336 Proadifen .HCl 286 Allobarbital 337 Thiamylal 287 Naproxen 338 Fenethylline 288 Xanthine 339 Strychnine 289 Thiothixene 340 Quinidine 290 Aprobarbital 341 Quinine 291 Hexobarbital 342 Brucine 292 Isoniazid 343 Tybamate 293 Ethopropazine 344 Fentanyl 294 5-Ethyl-5-phenylhydantoin 345 Heptabarbital 295 2-Ethyl-2- 346 Sulfisoxazole phenylmalonamide 347 Piperazine 296 5-Methyl-5- 348 Protriptyline .HCl phenylhydantoin 349 Chlorphentermine .HCl 297 Propranolol 350 Talbutal 298 Quinethazone 351 Reserpine 299 N-Desalkyl flurazepam 352 Loxapine .HCl 300 2-Amino-5- 353 Warfarin chlorobenzophenone 354 4-Methyl-2,5- 301 Hydroxyamphetamine .HBr dimethoxyamphetamine 302 Haloperidol 355 Trichlormethiazide 303 Trifluoperazine .2HCl 356 Pseudococaine .HCl Georgia State Crime Lab Drug Library, page 4 of 21 Index Number Compound Name Index Number Compound Name 357 Thiopental 400 Nicotinic acid 358 Cyclazocine 401 Nalorphine 359 4-Aminoantipyrine 402 Tolazoline .HCl 360 Amoxapine 403 1-(1-(2- 361 Kbr blank Thienyl)cyclohexyl)morphol 362 Sulfapyridine ine .HCl 363 Pemoline 404 Ampillicin, anhydrous 364 Metronidazole 405 Citral 365 Disulfiram 406 Olivetol; 5-Pentylresorcinol 366 Procarbazine .HCl 407 Tetracaine .HCl 367 Acetanilide 408 N-(N-Butyl)-1- 368 Phensuximide phenylcyclohexylamine 369 Chlorprothixene 409 l-a-Acetyl-N,N- 370 N,N-Diethyl-1- dinormethadol .HCl phenylcyclohexylamine 410 l-a-Acetyl-N-normethadol 371 Dyphylline .HCl 372 Methallatal 411 Quinacrine .HCl 373 N-(N-Propyl)-1- 412 Alprazolam phenylcyclohexylamine 413 p-Methylamphetamine .HCl sulfate 374 Rescinnamine 414 Desonide 375 5-(o-Methylphenyl)-5- 415 Colchicine phenylhydantoin 416 p-Aminobenzoic acid 376 Naphazoline 417 dl-Synephrine 377 N-Methyl-1- 418 Sulfamethoxazole phenylcyclohexylamine 419 Xylometazoline .HCl 378 Ethosuximide 420 Atropine 379 N-(Isopropyl)-1- 421 dl-p-Chloroamphetamine phenylcyclohexylamine .HCl .HCl 422 Theobromine; 3,7- 380 Butethal Dimethylxanthine 381 Ethinamate 423 N-Acetylprocainamide .HCl 382 Thiobarbital 424 7-(2- 383 Thebaine Hydroxyethyl)theophylline;
Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • House Bill No. 1176

    House Bill No. 1176

    FIRST REGULAR SESSION HOUSE BILL NO. 1176 101ST GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE DAVIS. 2248H.01I DANA RADEMAN MILLER, Chief Clerk AN ACT To repeal sections 191.480 and 579.015, RSMo, and to enact in lieu thereof two new sections relating to investigational drugs. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Sections 191.480 and 579.015, RSMo, are repealed and two new sections 2 enacted in lieu thereof, to be known as sections 191.480 and 579.015, to read as follows: 191.480. 1. For purposes of this section, the following terms shall mean: 2 (1) "Eligible patient", a person who meets all of the following: 3 (a) Has a debilitating, life-threatening, or terminal illness; 4 (b) Has considered all other treatment options currently approved by the United States 5 Food and Drug Administration and all relevant clinical trials conducted in this state; 6 (c) Has received a prescription or recommendation from the person's physician for an 7 investigational drug, biological product, or device; 8 (d) Has given written informed consent which shall be at least as comprehensive as the 9 consent used in clinical trials for the use of the investigational drug, biological product, or device 10 or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or 11 legal guardian has given written informed consent on the patient's behalf; and 12 (e) Has documentation from the person's physician that the person has met the 13 requirements of this subdivision; 14 (2) "Investigational drug, biological product, or device", a drug, biological product, or 15 device, any of which are used to treat the patient's debilitating, life-threatening, or terminal 16 illness, that has successfully completed phase one of a clinical trial but has not been approved EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
  • The Effects of Oral Administration of the Novel Muscarinic Receptor

    The Effects of Oral Administration of the Novel Muscarinic Receptor

    Choi et al. BMC Urology (2020) 20:41 https://doi.org/10.1186/s12894-020-00611-8 RESEARCH ARTICLE Open Access The effects of oral administration of the novel muscarinic receptor antagonist DA- 8010 on overactive bladder in rat with bladder outlet obstruction Jin Bong Choi1, Seung Hwan Jeon2, Eun Bi Kwon3, Woong Jin Bae4, Hyuk Jin Cho2, U-Syn Ha2, Sung-Hoo Hong2, Ji Youl Lee2 and Sae Woong Kim4* Abstract Background: DA-8010 is a novel compound developed for the treatment of overactive bladder (OAB) and urinary incontinence. The aims of this study were to investigate the effects of DA-8010 on OAB in a rat model. Methods: Study animals were divided into the following five groups of seven animals each: a sham-operated control group, a control group with partial bladder outlet obstruction (BOO) (OAB group), and three DA-8010 (doses of 0.3 mg/kg/day, 1 mg/kg/day, and 3 mg/kg/day, respectively) with partial BOO groups. Oral administration of the drugs was continued for 14 days after 2 weeks of partial BOO. After 4 weeks of partial BOO, cystometrography was performed in all groups. Additionally, pro-inflammatory cytokines, Rho-kinases, and histology of the bladder were analyzed. Results: There was a significant increase in the contraction interval and a decrease in contraction pressure in the 3 mg/kg/day DA-8010 group versus those in the OAB group. Rho kinase was also significantly decreased in the DA- 8010 3 mg/kg/day dosage treatment group. The increased ratio of collagen to smooth muscle after partial BOO was significantly attenuated in the DA-8010 3 mg/kg/day dosage group.
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS

    Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS

    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
  • Development and Validation of an Ultra-Fast and Sensitive Microflow

    Development and Validation of an Ultra-Fast and Sensitive Microflow

    Drug Testing Research article and Analysis Received: 6 June 2016 Revised: 9 July 2016 Accepted: 10 July 2016 Published online in Wiley Online Library: 10 August 2016 (www.drugtestinganalysis.com) DOI 10.1002/dta.2042 Development and validation of an ultra-fast and sensitive microflow liquid chromatography- tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans Andrea E. Steuer,a* Michael Poetzsch,a Lorena Stock,a Lisa Eisenbeiss,a Yasmin Schmid,b Matthias E. Liechtib and Thomas Kraemera Lysergic acid diethylamide (LSD) is a semi-synthetic hallucinogen that has gained popularity as a recreational drug and has been investigated as an adjunct to psychotherapy. Analysis of LSD represents a major challenge in forensic toxicology due to its insta- bility, low drug concentrations, and short detection windows in biological samples. A new, fast, and sensitive microflow liquid chromatography (MFLC) tandem mass spectrometry method for the validated quantification of LSD, iso-LSD, 2-oxo 3-hydroxy- LSD (oxo-HO-LSD), and N-desmethyl-LSD (nor-LSD) was developed in plasma and applied to a controlled pharmacokinetic (PK) study in humans to test whether LSD metabolites would offer for longer detection windows. Five hundred microlitres of plasma were extracted by solid phase extraction. Analysis was performed on a Sciex Eksigent MFLC system coupled to a Sciex 5500 QTrap. The method was validated according to (inter)-national guidelines. MFLC allowed for separation of the mentioned analytes within 3 minutes and limits of quantification of 0.01 ng/mL.
  • Ranvet's Filybol

    Ranvet's Filybol

    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 10/28/2016 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified Non-virilising anabolic combination for fillies, mares, colts and stallions. uses Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex Legend: VI Label elements GHS label elements SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 10/28/2016 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants

    Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants

    MedDocs Publishers ISSN: 2638-1370 Annals of Clinical Nutrition Open Access | Mini Review Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants Ali Zaid A Alshehri1,2*; Mohammed saeed Al Qahtani1,3; Mohammed Aedh Al Qahtani1,4; Abdulhadi M Faeq1,5; Jawad Aljohani1,6; Ammar AL-Farga7 1Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia 2Poison Control and Medical Forensic Chemistry Center, Ministry of Health, Riyadh, Saudi Arabia 3Khammis Mushayte Maternity & Children Hospital, Ministry of Health, Saudi Arabia 4Ahad Rufidah General, Hospital, Aseer, Ministry of Health, Saudi Arabia 5Comprehensive Specialized Clinics of Security Forces in Jeddah, Ministry of Interior, Saudi Arabia 6Compliance Department, Yanbu Health Sector, Ministry of Health, Saudi Arabia 7Department of Biochemistry, Faculty of Science, University of Jeddah, Saudi Arabia *Corresponding Author(s): Ali Zaid A Alshehri Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia Email: [email protected] Received: Apr 27, 2020 Accepted: Jun 05, 2020 Published Online: Jun 10, 2020 Journal: Annals of Clinical Nutrition Publisher: MedDocs Publishers LLC Online edition: http://meddocsonline.org/ Copyright: © Alshehri AZA (2020). This Article is distributed under the terms of Creative Commons Attribution 4.0 International License Introduction ATS are synthetic compounds belonging to the class of stimu- and heroin users combined [3,4]. Fenethylline, 7-(2-amethyl lants that excite the Central Nervous System (CNS) to produce phenyl-amino ethyl)-theophylline, is a theophylline derivative of adrenaline-like effects such as amphetamine, methamphet- amphetamine. It is a psychoactive drug which is similar to am- amine, fenethylline, methylphenidate and dextroamphetamine phetamine in many ways [5].
  • EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011)

    EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011)

    EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011) 912 final COMMISSION STAFF WORKING PAPER on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Accompanying the document REPORT FROM THE COMMISSION on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances {COM(2011) 430 final} EN EN TABLE OF CONTENTS 1. Introduction...................................................................................................................3 2. Methodology.................................................................................................................4 3. Key findings from the 2002 evaluation of the Joint Action on synthetic drugs ...........5 4. Overview of notifications, types of substances and trends at EU level 2005-2010......7 5. Other EU legislation relevant for the regulation of new psychoactive substances.....12 6. Functioning of the Council Decision on new psychoactive substances .....................16 7. Findings of the survey among Member States............................................................17 7.1. Assessment of the Council Decision ..........................................................................17 7.2. Stages in the functioning of the Council Decision .....................................................18 7.3. National responses to new psychoactive substances ..................................................20
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Us Anti-Doping Agency

    Us Anti-Doping Agency

    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
  • Stability Study of Cannabidiol in the Form of Solid Powder and Sunflower Oil Solution

    Stability Study of Cannabidiol in the Form of Solid Powder and Sunflower Oil Solution

    pharmaceutics Article Stability Study of Cannabidiol in the Form of Solid Powder and Sunflower Oil Solution Ema Kosovi´c 1,2 , David Sýkora 2 and Martin Kuchaˇr 3,* 1 Institute of Chemical Process Fundamentals of CAS v.v.i., Rozvojová 135, 16502 Prague, Czech Republic; [email protected] 2 Department of Analytical Chemistry, University of Chemistry and Technology Prague, Technická 5, 16628 Prague, Czech Republic; [email protected] 3 Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, 16628 Prague, Czech Republic * Correspondence: [email protected] Abstract: Stability studies represent an essential component of pharmaceutical development, en- abling critical evaluation of the therapeutic potential of an active pharmaceutical ingredient (API) or a final pharmaceutical product under the influence of various environmental factors. The aim of the present study was to investigate the chemical stability of cannabidiol (CBD) in the form of a solid powder (hereinafter referred to as CBD powder) and also dissolved in sunflower oil. We performed stress studies in accordance with the International Conference on Harmonization (ICH) guidelines, where 5 mg of marketed CBD in the form of a solid powder and in form of oil solution were exposed for 7 and 14, 30, 60, 90, 180, 270, and 365 days to precisely defined temperature and humidity conditions, 25 ◦C ± 2 ◦C/60% RH ± 5% and 40 ◦C ± 2 ◦C/75% RH ± 5% in both open and closed vials in the dark. CBD powder was significantly more stable than CBD in oil solution. Such finding is important because CBD is often administered dissolved in oil matrix in practice due to Citation: Kosovi´c,E.; Sýkora, D.; very good bioavailability.